Wockhardt spurts over 33% in two sessions

Wockhardt hit an upper circuit limit of 20% at Rs 616.50 at 14:33 IST on BSE, extending Friday's 10.87% jump triggered by stock exchanges revising circuit filter on the stock from 5% to 20% with effect from Friday, 6 September 2013.

Meanwhile, the BSE Sensex was up 654.02 points, or 3.39%, to 19,924.08

On BSE, 6.81 lakh shares were traded in the counter compared with average volume of 2.17 lakh shares in the past one quarter.

The stock hit a high of Rs 616.50 and a low of Rs 532 so far during the day. The stock hit a 52-week low of Rs 344.15 on 8 August 2013. The stock hit a record high of Rs 2,166.05 on 12 March 2013.

Wockhardt shares jumped 10.87% to Rs 513.75 on Friday, 6 September 2013. The stock has risen 33.04% in two trading sessions from Rs 463.40 on 5 September 2013.

The stock had outperformed the market over the past one month till 6 September 2013, rising 34.74% compared with the Sensex's 2.87% rise. The scrip had, however, underperformed the market in past one quarter, sliding 57.03% as against Sensex's 1.28% fall.

The mid-cap company has an equity capital of Rs 54.88 crore. Face value per share is Rs 5.

Wockhardt's promoter group company, Khorakiwala Holdings & Investments, acquired 2.11 lakh equity shares representing 0.20% stake of the pharmaceutical company via market purchase in past trading sessions, data suggests.

Khorakiwala Holdings & Investments bought 50,000 shares each on 30 August, 2 September 2013 and 3 September 2013, while it purchased 61,094 shares on 4 September 2013, through open market purchase, according to information filed by the company with the stock exchanges.

Post acquisition, Khorakiwala Holdings & Investments' holding in Wockhardt has increased to 64.08% from 63.88% earlier.

As on 30 June 2013, Khorakiwala Holdings & Investments held 6.97 crore shares, or 63.62% stake in Wockhardt.

On a consolidated basis, Wockhardt's net profit fell 14.5% to Rs 323.31 crore on 1.3% increase in net sales to Rs 1358.37 crore in Q1 June 2013 over Q1 June 2012.

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has three research centres globally and manufacturing facilities across India, USA, UK and Ireland. The company has a significant presence in USA, Europe and India.

Powered by Capital Market - Live News